Preferred Second-Line Treatment Strategies in Relapsed/Refractory Follicular Lymphoma

Panelists discuss how the choice of second-line therapy for follicular lymphoma depends on multiple factors, including disease biology, prior responses, and patient goals. When the first course of treatment no longer provides benefit, the next step is tailored to maximize disease control while minimizing adverse effects. Advances in targeted and immune-directed therapies allow oncologists to offer more precise and durable responses, giving patients additional options when conventional regimens are no longer sufficient.

Newer treatment approaches have reshaped the second-line setting by focusing on mechanisms that target specific cellular markers involved in lymphoma growth. This precision reduces harm to healthy cells and often results in better tolerability. Physicians also consider each patient’s prior treatments, comorbidities, and tolerance for potential risks such as immune-related adverse effects. This ensures the selected therapy supports both disease management and the patient’s overall well-being.

A collaborative care model empowers patients to take an active role in treatment decisions. As second-line strategies expand, education and shared decision-making are essential so patients can weigh the benefits and potential risks of emerging therapies. With continuous innovation, the second-line setting increasingly serves as a bridge to advanced therapies that may offer deeper remissions and improved quality of life.